Bristol-Myers will lay off yet another 10%

Bristol-Myers Squibb will be handing layoff notices to another 10 percent of its 37,000 remaining workers, likely due to weak pipelines, increasing regulatory burdens, looming generic competition and (do we even need to say it?) the economy. This, along with a 10 percent cut the company announced in July of this year, will bring the total to 8,000 layoffs.

The cuts will occur through 2010, but 800 people will lose their jobs before this year is through. The layoffs are part of a streamlining effort and an attempt to lower costs by $2.5 billion before 2013 to address upcoming challenges, although the company has had a good sales run with Abilify, Erbitux and Plavix recently. According to the Wall Street Journal, the cuts will be company-wide and global, and will include researchers as well as sales staff. 

The pharma giant joins other huge industry players that are sending employees to the unemployment line, including Abbott, AstraZeneca, GlaxoSmithKline, Merck and Pfizer. It might be that big pharma companies finally are finding their ways to becoming right-sized, but employees and shareholders are not happy to be holding the bag for some less-than-stellar planning.

Bristol-Myers Squibb also sold Convatec, its wound care unit (which had another 3,400 employees), in May. At around the same time it attempted to purchase ImClone, but lost to Eli Lilly.

- here's the Associated Press story
- read more in the Wall Street Journal 
- find the Wall Street Journal blog post

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.